10-Q: International Isotopes Inc. Reports Improved Q3 Results Driven by Theranostics and Cobalt Sales

International Isotopes Inc. saw a significant improvement in its third-quarter results, driven by increased sales in its Theranostics and Cobalt product segments, despite a global shortage impacting its Nuclear Medicine Standards business.

Summary

• International Isotopes Inc. reported a net income of $150,251 for the three months ended September 30, 2024, compared to a net loss of $348,605 for the same period in 2023.
• The company's revenue increased by 34% to $3,924,444 in Q3 2024, up from $2,918,556 in Q3 2023.
• Gross profit also saw a significant increase, rising to $2,449,428 in Q3 2024 from $1,792,668 in Q3 2023.
• The Theranostics Products segment experienced a 42% increase in revenue, reaching $2,183,197 in Q3 2024.
• Cobalt Products revenue increased by 148% to $814,845 in Q3 2024.
• However, the Nuclear Medicine Standards segment saw a 12% decrease in revenue, falling to $926,402 due to a global shortage of Cobalt-57 isotope.
• For the nine months ended September 30, 2024, the company's net loss was $237,245, a significant improvement from the $759,961 loss in the same period of 2023.
• The company's total revenue for the first nine months of 2024 was $9,998,135, a 10% increase compared to $9,120,256 in the same period of 2023.
• The company expects that cash from operations, equity financing, and current cash balance will be sufficient to fund operations for the next twelve months.

Sentiment

Score: 7

Explanation: The document shows a positive trend with improved financial results and strategic initiatives, but there are still some challenges and risks that need to be addressed. The company is showing signs of recovery and growth, but it is not without its challenges.

Positives

• The company's financial performance improved significantly in Q3 2024, with a return to profitability.
• The Theranostics and Cobalt segments showed strong revenue growth.
• Gross profit margins improved due to better pricing and efficient utilization of raw materials.
• The company has secured a contract with the DOE for the production of high specific activity cobalt.
• The company has added additional suppliers for Cobalt-57 and has seen a sharp decrease in cancellations of orders.
• The company has entered into a joint venture with Phantech LLC to form PhanQual to expand its Nuclear Medicine Standards segment.

Negatives

• The Nuclear Medicine Standards segment experienced a 12% revenue decrease in Q3 2024 due to a global shortage of Cobalt-57 isotope.
• Operating expenses increased by 8% in Q3 2024 due to waste disposal costs and investments in the Medical Device segment.
• The company incurred a net loss of $18,806 in the Cobalt Products segment for the nine months ended September 30, 2024, due to increased waste disposal costs.
• The company experienced a net loss of $328,743 in the Nuclear Medicine Standards segment for the nine months ended September 30, 2024, due to decreased revenue.
• The company has not yet commercialized any medical devices, and the Medical Device segment incurred operating expenses of $279,801 for the nine months ended September 30, 2024.

Risks

• The company's production of Cobalt-60 is dependent on the U.S. Department of Energy (DOE) and its prime operating contractor.
• Sales of Theranostics Products are dependent on a few key suppliers, and interruptions could negatively impact sales.
• The company's Nuclear Medicine Reference and Calibration Standard products are dependent on certain radioisotopes, and a loss of suppliers could affect operating results.
• The company's business segments involve the handling of radioactive material, requiring an operating license from the NRC and specially trained staff.
• The company's future liquidity and capital funding requirements depend on various factors, and there is no assurance that additional capital will be available on acceptable terms.
• The company is subject to regulatory risks associated with the handling and use of radioactive materials.

Future Outlook

The company expects continued sales growth for its Theranostics products, primarily from the sale of its generic sodium iodide I-131 drug product and new sales of theranostic API product. The company also expects increased revenue in the Nuclear Medicine Standards segment as the global isotope supply chain normalizes. The company anticipates commercialization of medical devices starting later in 2024. The company expects that cash from operations, equity financing, and current cash balance will be sufficient to fund operations for the next twelve months.

Management Comments

• The company continued its focus on its strongest long-standing core business segments which consist of its Theranostics Products, Cobalt Products, and Nuclear Medicine Standards.
• The company has begun to focus on the start-up of its Medical Device segment.
• The company expects increased revenue due to backlog catch-up throughout the remainder of 2024 and potentially into the first quarter of 2025 as our global isotope supply chain has normalized.

Industry Context

The company operates in the niche market of nuclear medicine and radiopharmaceuticals, which is characterized by high regulatory barriers and specialized manufacturing processes. The company's focus on theranostics and cobalt products aligns with the growing demand for targeted therapies and radiation sources. The global shortage of Cobalt-57 highlights the supply chain vulnerabilities in the industry.

Comparison to Industry Standards

• The company's revenue growth in the Theranostics segment is in line with the increasing adoption of targeted radiotherapies.
• The company's Cobalt Products segment is unique in the US, as it is the only company that can provide all the unique services.
• The company's Nuclear Medicine Standards segment is facing challenges due to the global shortage of Cobalt-57, which is impacting other companies in the industry as well.
• The company's gross profit margins in the Theranostics segment are competitive with other radiopharmaceutical manufacturers.
• The company's investment in the Medical Device segment is a strategic move to diversify its revenue streams and capitalize on the growing demand for medical devices in the radiopharmaceutical space.
• The company's reliance on the DOE for cobalt production is a common practice in the industry, but it also presents a risk if the contract is terminated.

Legal Proceedings

• The company has resolved a matter with the NRC related to a violation that occurred in 2022.

Related Party Transactions

• The company has promissory notes with its former Chairman of the Board, its Chief Executive Officer and Chairman of the Board, and four major shareholders.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and growth prospects.
• Employees will benefit from the company's continued operations and growth.
• Customers will benefit from the company's continued supply of products and services.
• Suppliers will benefit from the company's continued demand for raw materials and services.
• Creditors will benefit from the company's improved financial stability.

Next Steps

• The company will continue to focus on its core business segments and pursue new business opportunities.
• The company will work on the start-up of its Medical Device segment and commercialize products in 2025.
• The company will continue to work with the DOE on an extension to the contract for future irradiation and supply of Cobalt.
• The company will continue to search for additional means to produce and procure certain critical isotopes.
• The company will work to close the agreement to sell all of its assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility.

Key Dates

Keywords

Theranostics, Cobalt-60, Nuclear Medicine, Radioisotopes, Medical Devices, Iodine-131, Cobalt-57, Radiopharmaceuticals, Calibration Standards, Joint Venture